Close Menu

NEW YORK – A new study in advanced melanoma patients by researchers in Germany has found that tumor mutation burden (TMB), circulating tumor DNA (ctDNA), and cell-free DNA can predict response to combined immunotherapy and overall survival under the treatment.

In particular, treatment failure could be detected as early as three weeks after the start of therapy using ctDNA and cfDNA, which might help doctors and patients decide whether to continue treatment if adverse events occur early.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.